Preparation and photoelectrochemical characterization of WO3/TiO2 nanotube array electrode

WO3/TiO2 nanotube array electrode was fabricated by incorporating WO3 with TiO2 nanotube array via a wet impregnation method using ammonium tungstate as the precursor. TiO2 and WO3/TiO2 nanotube arrays were characterized by field emission scanning electron microscopy, X-ray diffraction, and energy dispersive X-ray analysis. In order to characterize the photoelectrochemical properties of WO3/TiO2 electrode, electrochemical impedance spectroscopy, and steady-state photocurrent (i(ss)) measurement at a controlled potential were performed in the supporting electrolyte containing different concentrations of glucose. The photoelectrochemical characterization results reveal that WO3/TiO2 nanotube array electrode possesses a much higher separation efficiency of the photogenerated electron-hole pairs and could generate more photoholes on the electrode surface compared with the pure TiO2 nanotube array electrode. The i(ss) for glucose oxidation at WO3/TiO2 nanotube array electrode is much higher than that at the pure TiO2 nanotube array electrode

Retrospective Evaluation of New Chinese Diagnostic Scoring System for Disseminated Intravascular Coagulation.

To retrospectively validate the new Chinese DIC scoring system (CDSS).This study retrospectively collected the information of 619 patients (371 cases with non-hematologic malignancies, 248 cases with hematologic malignancies) who suspected of DIC in Wuhan Union Hospital during 2013-4 to 2014-6. We validated CDSS by comparing it with three leading scoring systems, from International Society on Thrombosis and Haemostasis (ISTH), Japanese Association for Acute Medicine (JAAM) and Japanese Ministry of Health and Welfare (JMHW), and evaluated its prognostic value by 28 days mortality, APACHE II and SOFA score.In non-hematologic malignancies, CDSS was more specific than JAAM (72.55% vs. 50.49%, p<0.05) and more sensitive than ISTH (77.07% vs. 62.03%, p<0.05). In hematologic malignancies, the area under the ROC curve of CDSS was larger than ISTH and JMHW (0.933 vs. 0.889, p<0.01 with ISTH, 0.944 vs. 0.845, p<0.01 with JMHW). In addition, the 28-day mortality rate, SOFA scores, APACHE II scores of DIC patients diagnosed by CDSS were significantly greater than non-DIC (P <0.05).We are the first group to propose CDSS. It emphasized the values of the clinical manifestations, the rapidly declining platelet count, APTT in the diagnosis of DIC and used D-dimer as the fibrin-related maker. DIC with hematological malignancies was treated as a special part. In this study we can see that CDSS displayed an acceptable property for the diagnosis of DIC with appropriate sensitivity and specificity, and also had a good prognostic value for DIC patients

Image1_Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker.TIF

Background: IGSF10 is a member of the immunoglobulin superfamily. Over the previous decade, growing proof has validated definitive correlations between individuals of the immunoglobulin superfamily and human diseases. However, the function of IGSF10 in pan-cancer stays unclear. We aimed to analyze the immunological and prognostic value of IGSF10 in pan-cancer.Methods: We utilized a vary of bioinformatic ways to inspect the function of IGSF10 in pan-cancer, including its correlation with prognosis, immune cell infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), DNA methyltransferases, genetic alteration, drug sensitivity, etc.Results: We noticed low expression of IGSF10 in most cancer types. IGSF10 expression in tumor samples correlates with prognosis in most cancers. In most cancer types, IGSF10 expression was strongly related to immune cells infiltration, immune checkpoints, immune modulators, TMB, MSI, MMR, and DNA methyltransferases, among others. Functional enrichment analyses indicated that IGSF10 expression was involved in lymphocyte differentiation, cell molecules adhesion, etc. Furthermore, low IGSF10 expression could increase the drug sensitivity of many drugs.Conclusion:IGSF10 could serve as a novel prognostic marker and attainable immunotherapy target for several malignancies.</p

Revealing mechanism of Methazolamide for treatment of ankylosing spondylitis based on network pharmacology and GSEA

Abstract Methazolamide is a carbonic anhydrase (CA) inhibitor with satisfactory safety. Our previous studies have demonstrated the elevation of CA1 expression and the therapeutic effect of Methazolamide in Ankylosing spondylitis (AS). In this study, we explored the pathogenic role of CA1 and the pharmacological mechanism of Methazolamide in AS through Gene Set Enrichment Analysis (GSEA) and network pharmacology. Seven out of twelve CA1 related gene sets were enriched in AS group. CA1 was core enriched in above seven gene sets involving zinc ion binding, arylesterase activity and one carbon metabolic process. Functional analysis of the candidate target genes obtained from the intersection of AS associated genes and Methazolamide target genes indicated that Methazolamide exerts therapeutic effects on AS mainly through inflammatory pathways which regulate the production of tumor necrosis factor, IL-6 and nitric oxide. PTGS2, ESR1, GSK3β, JAK2, NOS2 and CA1 were selected as therapeutic targets of Methazolamide in AS. Molecular docking and molecular dynamics simulations were performed successfully. In addition, we innovatively obtained the intersection of Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses and GSEA results, and found that 18 GO terms and 5 KEGG terms were indicated in the pharmacological mechanism of Methazolamide in AS, involving bone mineralization, angiogenesis, inflammation, and chemokine signaling pathways. Nevertheless, validation for these mechanisms is needed in vivo/vitro experiments

Disease Sequences High-Accuracy Alignment Based on the Precision Medicine

High-accuracy alignment of sequences with disease information contributes to disease treatment and prevention. The results of multiple sequence alignment depend on the parameters of the objective function, including gap open penalties (GOP), gap extension penalties (GEP), and substitution matrix (SM). Firstly, the theory parameter formulas relating to GOP, GAP, and SM are inferred, combining unaligned sequence length, number, and identity. Secondly, we tested the rationality of the theory parameter formulas, with experiment on the ClustalW and MAFFT program. In addition, we obtained a group of MAFFT program parameters according to the formulas proposed. The results of all experiments show that the SPS (sum-of-pair score) obtained from theory parameters is better than the SPS obtained from the default parameters of ClustalW and MAFFT. In both theory and practice, our method to determine the parameters is feasible and efficient. These can provide high-accuracy alignment results for precision medicine

The flow diagram of the whole study process.

<p>The flow diagram of the whole study process.</p

Chinese DIC Scoring System (CDSS).

<p>Diagnosis: Seven points or more.</p><p>*If underlying disease is hematological malignancy:1.ignore item(1) from Clinical manifestations; 2.Platelet count: PLT<50×10⁹/l:1point,≥50% decrease within 24 hrs:1point; 3.Diagnosis: Six points or more. PT, prothrombin time. APTT, activated partial thromboplastin time.</p><p>Chinese DIC Scoring System (CDSS).</p

Characteristics of the diagnosis and mortality by each criterion in non- hematological malignancy.

<p>ISTH, International Society on Thrombosis and Haemostasis; JMHW, Japanese Ministry of Health and Welfare; JAAM, Japanese Association for Acute Medicine; CDSS, Chinese DIC scoring system; DIC, disseminated intravascular coagulation; AUC, area under receiver operating characteristic curve; OR, Odds ratio; CI, confidence interval.</p><p>a:p<0.05 for CDSS compared with other criteria;</p><p>b:p>0.05 for CDSS compared with other criteria;</p><p>c:P>0.05 between JAAM and ISTH;</p><p>*P>0.05 between any two;</p><p>#p<0.05 for each OR.</p><p>Characteristics of the diagnosis and mortality by each criterion in non- hematological malignancy.</p

Characteristics of DIC and non-DIC patients diagnosed by CDSS.

<p>*: sort order (infection, solid tumors, autoimmune diseases, trauma/post-surgery/poisoning, obstetric complications, vascular anomalies, shock/hypoxic-ischemic, severe liver disease, unknown reason, hematological malignancy); CDSS, Chinese DIC scoring system; DIC, disseminated intravascular coagulation; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; PLT, Platelet counts; APTT, activated partial thromboplastin time; PT, Prothrombin time; FDP, fibrin/fibrinogen degradation products; ATA, Antithrombotic Agents.</p><p>Characteristics of DIC and non-DIC patients diagnosed by CDSS.</p